Peripheral Arterial Disease Clinical Trial
Official title:
Blood Flow Restricted Resistance Training in Peripheral Arterial Disease: a Randomised Controlled Trial Feasibility Study
Verified date | November 2022 |
Source | Sheffield Hallam University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
A randomised controlled trial evaluating the feasibility and acceptability of a 12 week lower body blood flow restricted resistance exercise programme for people with peripheral arterial disease.
Status | Completed |
Enrollment | 30 |
Est. completion date | April 30, 2022 |
Est. primary completion date | March 5, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Men and women with PAD 6 months post diagnosis. - Ankle-brachial pressure index <0.9. - People physically able to perform leg press and leg extension resistance exercise. Exclusion Criteria: - Ankle-brachial pressure index >0.89. - People unable to visit the laboratory twice weekly for exercise sessions. - People unable to do leg press and leg extension exercise. - People whose walking is limited by a non-PAD condition. - People with PAD with critical limb ischemia (including symptoms of pain at rest and skin ulcers). - People with Dementia. - People who have had major surgery or myocardial infarction within the past 6 months. - Previous stroke. - Previous thrombosis. - People who have major surgery scheduled during the intervention period. |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Sheffield Hallam University | Sheffield | South Yorkshire |
Lead Sponsor | Collaborator |
---|---|
Sheffield Hallam University | Sheffield Teaching Hospitals NHS Foundation Trust |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Recruitment Rates | Defined as rate of invited participants who are eligible and consenting. | 3 months | |
Primary | Retention Rates | Retention rates will be established as discontinuation with the exercise intervention and absence from the assessment sessions. | 3 months | |
Primary | Acceptability of allocation | will be assessed by attrition rates, comparing participant withdrawal between experimental and control groups and reasons for dropout where appropriate. | 3 months | |
Primary | Acceptability of the exercise study | Will be evaluated by participants feedback via one-to-one semi-structured interviews. | 3 months | |
Primary | Completion Rates | Completion is determined by participants that attend baseline testing and post exercise intervention testing. | 3 months | |
Secondary | Change in PAD severity | ankle-brachial pressure index | 3 months | |
Secondary | Change in muscle size | Size of vastus lateralis measured via ultrasound | 3 months | |
Secondary | Change in strength | Unilateral isometric maximal voluntary contraction | 3 months | |
Secondary | Change in walk ability | Measured via the 6-minute walk test | 3 months | |
Secondary | Change in physical function | Measured via timed up-and-go test | 3 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06032065 -
Sequential Multiple Assessment Randomized Trial of Exercise for PAD: SMART Exercise for PAD (SMART PAD)
|
Phase 3 | |
Active, not recruiting |
NCT03987061 -
MOTIV Bioresorbable Scaffold in BTK Artery Disease
|
N/A | |
Recruiting |
NCT03506633 -
Impacts of Mitochondrial-targeted Antioxidant on Peripheral Artery Disease Patients
|
N/A | |
Active, not recruiting |
NCT03506646 -
Dietary Nitrate Supplementation and Thermoregulation
|
N/A | |
Active, not recruiting |
NCT04677725 -
NEtwork to Control ATherothrombosis (NEAT Registry)
|
||
Recruiting |
NCT05961943 -
RESPONSE-2-PAD to Reduce Sedentary Time in Peripheral Arterial Disease Patients
|
N/A | |
Recruiting |
NCT06047002 -
Personalised Antiplatelet Therapy for Patients With Symptomatic Peripheral Arterial Disease
|
||
Completed |
NCT03185052 -
Feasibility of Outpatient Care After Manual Compression in Patients Treated for Peripheral Arterial Disease by Endovascular Technique With 5F Sheath Femoral Approach
|
N/A | |
Recruiting |
NCT05992896 -
A Study of Loco-Regional Liposomal Bupivacaine Injection
|
Phase 4 | |
Completed |
NCT04635501 -
AbsorbaSeal (ABS 5.6.7) Vascular Closure Device Trial
|
N/A | |
Recruiting |
NCT04584632 -
The Efemoral Vascular Scaffold System (EVSS) for the Treatment of Patients With Symptomatic Peripheral Vascular Disease From Stenosis or Occlusion of the Femoropopliteal Artery
|
N/A | |
Withdrawn |
NCT03994185 -
The Merit WRAPSODY™ Endovascular Stent Graft for Treatment of Iliac Artery Occlusive Disease
|
N/A | |
Withdrawn |
NCT03538392 -
Serranator® Alto Post Market Clinical Follow Up (PMCF) Study
|
||
Recruiting |
NCT02915796 -
Autologous CD133(+) Cells as an Adjuvant to Below the Knee Percutaneous Transluminal Angioplasty
|
Phase 1 | |
Active, not recruiting |
NCT02900924 -
Observational Study to Evaluate the BioMimics 3D Stent System: MIMICS-3D
|
||
Completed |
NCT02901847 -
To Evaluate the Introduction of a Public Health Approach to Peripheral Arterial Disease (PAD) Using National Centre for Sport and Exercise Medicine Facilities.
|
N/A | |
Not yet recruiting |
NCT02455726 -
Magnesium Oral Supplementation to Reduce Pain Inpatients With Severe Peripheral Arterial Occlusive Disease
|
N/A | |
Not yet recruiting |
NCT02387450 -
Reduced Cardiovascular Morbi-mortality by Sildenafil in Patients With Arterial Claudication
|
Phase 2/Phase 3 | |
Withdrawn |
NCT02126540 -
Trial of Pantheris System, an Atherectomy Device That Provides Imaging While Removing Plaque in Lower Extremity Arteries
|
N/A | |
Completed |
NCT02384980 -
Saving Life and Limb: FES for the Elderly With PAD
|
Phase 1 |